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With the rise of various multidrug-resistant (MDR) pathogenic bacteria, worldwide
health care is under pressure to respond. Conventional antibiotics are failing and the
development of novel classes and alternative strategies is a major priority. Antimicrobial
peptides (AMPs) cannot only kill MDR bacteria, but also can be used synergistically
with conventional antibiotics. We selected 30 short AMPs from different origins and
measured their synergy in combination with polymyxin B, piperacillin, ceftazidime,
cefepime, meropenem, imipenem, tetracycline, erythromycin, kanamycin, tobramycin,
amikacin, gentamycin, and ciprofloxacin. In total, 403 unique combinations were
tested against an MDR Pseudomonas aeruginosa isolate (PA910). As a measure
of the synergistic effects, fractional inhibitory concentrations (FICs) were determined
using microdilution assays with FICs ranges between 0.25 and 2. A high number of
combinations between peptides and polymyxin B, erythromycin, and tetracycline were
found to be synergistic. Novel variants of indolicidin also showed a high frequency in
synergist interaction. Single amino acid substitutions within the peptides can have a
very strong effect on the ability to synergize, making it possible to optimize future drugs
toward synergistic interaction.
Keywords: multidrug resistance, Pseudomonas aeruginosa, antimicrobial peptides, synergy, revive old antibiotics
INTRODUCTION
Among the most serious problems health care is facing is the increased number of infections
caused by antibiotic-resistant bacteria, which can no longer be treated with previously active
antimicrobial agents. In 2013, the World Health Organization (WHO) identified the development
of antibiotic resistance as one of the major global threats to human society and recommended
intensive monitoring to identify critical hot spots, in order to reduce transmission. The global
spread of antibiotic resistance is one of the most interesting examples of biological evolution. It is
highly relevant to both human and animal health and welfare with a direct impact on society. The
primary cause of this situation is the excessive use of antibiotics (Berendonk et al., 2015). Although
environmental bacteria are most probably the original source of many antibiotic resistance genes
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found in bacterial pathogens, the impact of nosocomial resistance
and transmission has greatly increased over the last half century
(Bush et al., 2011). The increased prevalence of antibiotic
resistance in microbiota is due to four major factors: (i)
the horizontal transfer of antibiotic-resistant genes, (ii) the
assortment of resistant bacteria due to selective pressures
from antimicrobial usage, (iii) the bacterial capability for
gene mutation and recombination (e.g., presence of mutator
determinants) (Wright and Sutherland, 2007; Davies and Davies,
2010; Cantón and Morosini, 2011), and (iv) the dissemination of
resistant organisms from human and animal commensals that
have adapted to antibiotic treatment of the host. Importantly,
we cannot exclude the proliferation of antibiotic resistance
due to the spread of resistant bacterial clones and their
mobile genetic elements carrying antibiotic-resistance genes.
This is due to spontaneous processes not necessarily linked
with antibiotic resistance (Kohanski et al., 2010; Seiler and
Berendonk, 2012; Baquero et al., 2013). Though the over-
use of antibiotics may cause resistant populations, other
biotic and abiotic factors including physicochemical conditions,
pollution, induction of stress responses, bacterial adaptation,
and phenotypic heterogeneity inter alia can enhance the effect
of selective pressure. Evidence has shown that even in sub-
inhibitory concentrations, antibiotics may still exert their impact
on a microbial community (Andersson and Hughes, 2014).
The review of antimicrobial resistance in 2014 chaired by Jim
O’Neill and initiated by the UK prime minister, published in
2016, estimates that by 2050 more people (10 million) will die
each year from infections than the current number of people who
die from cancer1. In order to maintain modern medical standards
of care, novel antimicrobials urgently need to be discovered
and developed, particularly those with novel modes of action,
which are less likely to suffer cross-resistance to existing drugs.
The WHO published a priority list in 20172 of bacteria that
are particularly problematic, in order to provide information
and focus for drug development projects. Carbapenem-resistant
Pseudomonas aeruginosa is in the highest category.
Pseudomonas aeruginosa is a rod-shaped, Gram-negative
bacterium, which is naturally found in soil and water and
therefore well adapted to humid environments. It is a clinically
important, opportunistic pathogen, which may cause pneumonia
and bacteremia in the elderly or immuno-compromised
hosts, and is responsible for chronic, destructive lung disease
in patients suffering from cystic fibrosis (Bhagirath et al.,
2016). P. aeruginosa exhibits a higher intrinsic resistance to
a number of antimicrobial agents compared to most other
Gram-negative bacteria and is one of the ESKAPE pathogens
(Yoneda et al., 2005). Additionally, rapid development of
resistance to previously effective antimicrobials, such as
fluoroquinolones, aminoglycosides, and polymyxins (Lupo et al.,
2018), has been observed.
Unfortunately, there has been a significant reduction in the
development of novel antimicrobial agents with many major
1https://amr-review.org/Publications.html
2http://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-
bacteria-for-which-new-antibiotics-are-urgently-needed
pharmaceutical companies halting research in anti-infective
agents. The fact there are very few new antimicrobial agents with
a new mode of action increases the risk of a nightmare scenario
where even “minor” infections could become serious health risks.
As there is already only a limited number of anti-pseudomonal
antibiotics and an increasing level of resistance, it is important to
ascertain whether potential new antibiotics with different modes
of action also synergize with “old” antimicrobials, especially for
multidrug resistant (MDR) bacteria.
Antimicrobial peptides (AMPs), also called host defense
peptides, represent a ubiquitous response in nature to overcome
microbial infections and compete for an ecological niche
(Hancock and Patrzykat, 2002). They are found in bacteria,
fungi, plants, and animals. These peptides have emerged as
central components of the innate defenses of both lower and
higher organisms. The antimicrobial activities can include actions
against Gram-negative and Gram-positive bacteria, including
mycobacteria, fungi, and enveloped viruses (Hancock, 2001;
Cole, 2003; Mania et al., 2010; Ramón-García et al., 2013;
Silva et al., 2016). Of particular interest is their ability to
kill MDR bacteria (Nuti et al., 2017). In addition, within
the last two decades, it has become increasingly clear that
various AMPs play a role in regulating the process of innate
immunity. It has been reported that some AMPs can have
direct and indirect chemotactic functions, regulate chemokine
and cytokine production, and promote wound healing (Territo
et al., 1989; Niyonsaba et al., 2002; Heilborn et al., 2003;
Elssner et al., 2004; Di Nardo et al., 2007; Carretero et al.,
2008). The direct antimicrobial activity has been studied on
some examples and multiple bacterial targets of AMPs were
discovered (Brogden, 2005), for example binding to RNA, DNA,
or histones (Kobayashi et al., 2000; Hale and Hancock, 2007; Cho
et al., 2009; Xie et al., 2011), blocking DNA-dependent enzymes
(Marchand et al., 2006; Hilpert et al., 2010), blocking the synthesis
of important outer membrane proteins (Carlsson et al., 1991),
binding to the chaperon DnaK and the ribosome (Krizsan
et al., 2015; Knappe et al., 2016; Mardirossian et al., 2018,
2019) and lipid 2 (de Leeuw et al., 2010; Schmitt et al., 2010).
In addition, the effect of such peptides on blood components
was studied (Yu et al., 2015). It is possible to use peptide
libraries to screen and optimize AMPs (Ashby et al., 2017). With
the already large number of AMPs and there various modes
of action, a method for classifying such peptides according
to their mode of action would be highly valuable. Recently,
BioSAXS was used to develop this type of classification method
(Von Gundlach et al., 2016, 2019).
Antimicrobial peptides will often be produced in abundance in
one organism, for example, on the skin of amphibians (Yang et al.,
2012). It has been shown that AMPs can synergize with each other
to create the desired biological effect, including antibacterial,
antitumor, and immunomodulatory action (Westerhoff et al.,
1995; Yan and Hancock, 2001; Pöppel et al., 2015; Rahnamaeian
et al., 2015; Hanson et al., 2019). Synergy between AMPs
and conventional antibiotics has been studied in vivo and
in vitro (Baindara et al., 2016; Otvos et al., 2018; Zharkova
et al., 2019). Since synergy could potentially be an important
feature for future drugs based on AMPs, we were interested in
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discovering the extent to which small changes in the peptide
sequence influence the synergy with conventional antibiotics.
In addition, we also investigated whether antibiotics with the
same target/mode of action would synergize with a peptide
in a similarly manner or not. In this study, we used MDR
P. aeruginosa and designed AMPs.
MATERIALS AND METHODS
Peptides and Antibiotics
The peptides used in this study were purchased from the Brain
Research Centre at the University of British Columbia. Peptides
were characterized and purified using high-performance liquid
chromatography (HPLC); mass was confirmed by matrix-assisted
laser desorption time of flight (MALDI-TOF) mass spectroscopy.
The purity of all peptides was greater than 90%.
The antibiotics were purchased from VWR, except polymyxin
B, which was purchased from Sigma-Aldrich.
Minimal Inhibitory Concentration
We selected six different P. aeruginosa isolates that were
described as MDR and had been isolated from clinical
and municipal waste water (Schwartz et al., 2006). The
minimal inhibitory concentration (MIC) was determined in a
microdilution assay using Mueller-Hinton (MH) broth following
a previously published protocol (Wiegand et al., 2008). Briefly,
a twofold serial dilution of the antibiotics and peptides were
prepared and added to a bacteria solution, resulting in 2–5
105 CFU/ml. The microtiter plates (polypropylene, Corning)
were incubated for 18 h at 37◦C and MICs were taken visually.
Fractional Inhibitory Concentration
The checkerboard assay was used to determine the fractional
inhibitory concentrations (FICs), following the protocol
described in Koneman’s Color Atlas and Textbook of Diagnostic
Microbiology (Winn et al., 2006). Briefly, combinations of
peptides and antibiotics were prepared in 96-well plates
(polypropylene, Corning) in a twofold dilution series. After the
addition of a log-phase bacterial inoculum of 2–5× 105 CFU/ml,
plates were incubated at 37◦C for 18 h. The FICs were determined
by visual inspection and the effects of the combinations were
determined using the FICs. The FIC was computed by adding
two partial FIC values, FICA—the MIC of drug A, tested in
combination with drug B divided by the MIC of drug A, tested
alone and FICB—the MIC of drug B, tested in combination
with drug A divided by the MIC of drug B, tested alone
[FIC = FICA + FICB = (MICAB/MICA) + (MICBA/MICB),
where MICA and MICB are the MICs of drugs A and B alone,
respectively, and MICAB and MICBA are the MIC concentrations
of the drugs in combination]. Here we use the European
Committee for Antimicrobial Susceptibility Testing (EUCAST)
definition, which is very similar to the definition provided by
Odds, 2003, except Odds define additive effects when FIC values
are between 0.5 and 1 (European Committee for Antimicrobial
Susceptibility Testing [EUCAST] of the European Society of
Clinical Microbiology and Infectious Diseases [ESCMID], 2000;
Odds, 2003). The combination of peptide (drug A) and
antibiotics (drug B) was defined as synergistic if the FIC
was ≤ 0.5, indifferent if the FIC was > 0.5 but ≤ 4.0 and
antagonistic if the FIC was> 4.0.
Statistical Analysis
A statistical binary outcome has been defined according to
two activity classes to analyze MIC values of the conventional
antibiotics. Class 0 is denoted as sensitive and is defined by values
below or equal to the EUCAST MIC breakpoint, while class 1 is
denoted as resistant and is defined by values above the EUCAST
MIC breakpoint. For the wild type (PA01), all tested antibiotics
with breakpoints were sensitive. Cross-tabulating PA01 and any
of PA910-PA253 would therefore not result in a proper 2 × 2
table, so a Fisher exact test would apply. However, given the
biological context, it is possible to build a valid one-sample
statistical test if we made the assumption that there is only
one resistance in PA01wt and use a binomial exact test (with
various approximations for 95% CI—only Wilson shown) for the
null hypothesis H0: pi = 0.1 against H1: pi 6= 0.1 (Van Belle and
Fisher, 2004). The assumption is that each resistance/sensitive
value along columns is independent of each other.
A four-category ordinal response variable has been generated
(from weak to strong in microbiological terms) to analyze the
MIC values of the AMPs. The levels of outcome status have a
natural ordering but the distances between adjacent levels are
unknown. To understand how these levels associate with class, a
natural approach is that of an ordinal logistic regression on class.
The key assumption in ordinal regression is that the effects of any
explanatory variables are consistent or proportional across the
different thresholds; hence, this is usually termed proportional
odds assumption (Van Belle and Fisher, 2004). A simple chi-
squared statistical test would be limited to producing a p-value
indicating the strength of the evidence against the null hypothesis
of independency between this outcome and class activity. The
advantage of an ordinal logistic regression is in that it numerically
quantifies this potential association between the effect of class and
this outcome derived from activity. All the analyses have been
performed using Stata Statistical Software: Release 15. College
Station, TX, United States: StataCorp LLC.
RESULTS
First, we determined the MIC values against a range of different
antibiotics for six strains of P. aeruginosa which were described
as MDR and had been isolated from clinical or municipal waste
water, in comparison with a sensitive wild type strain (PAO1)
(see Table 1; Schwartz et al., 2006). This confirmed that these
strains are MDR. The response of wild-type strain PA01 toward
the antibiotics was compared to the response of the six isolated
MDR strains for statistical analysis. This response was classified
into two groups, sensitive and resistant. The MIC EUCAST
breakpoints were used to make the distinction between resistant
(larger MIC than breakpoint) and sensitive (equal or lower MIC
than breakpoint). The resulting p-values from these tests indicate
strong evidence against the null, i.e., that all the proportions of
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TABLE 1 | MIC determination of conventional antibiotics against wild-type P. aeruginosa and MDR isolates (values in µM), at least three repeats for each value (n = 3).
Antibiotic/strain Break-point PA01-wt PA 910 PA 915 PA 919 PA 923 PA 927 PA253
Polymyxin B >1.7∗ 0.125 0.125 0.25 0.125 0.25 0.25 0.125
Ciprofloxacin >1.5 0.25 64 32 64 64 16 64
Tobramycin >8.5 0.25–0.5 32 64 64 32 32 64
Gentamycin >8.3 1 128 128–256 128 128 128 >256
Amikacin >27.3 1 2–4 4 32 4 4 8–16
Imipenem >13.4 2 >128 >128 16 > 128 >128 > 128
Meropenem >20.8 2–4 >128 >128 >128 >128 >128 >128
Piperacillin >30.9 4 64–128 >256 64 128 256 >256
Ceftazidime >14.6 4 128 4 8 128 >128 >128
Tetracyclin NA 8 64 16 32 >512 16 32
Cefepime >16.6 8 64 32 16 64 128 >128
Kanamycin NA 64 128–256 256–512 128 256 128 >512
Erythromycin NA 128 128 64 128 256 16 64
Proportion of resistance compared to wt 0.8 0.7 0.8 0.8 0.8 0.8
p-Values <0.000001 <0.000001 <0.000001 <0.000001 <0.000001 <0.000001
SE 0.13 0.14 0.13 0.13 0.13 0.13
95% Binomial CI (0.44, 0.97) (0.35, 0.93) (0.44, 0.97) (0.44, 0.97) (0.44, 0.97) (0.44, 0.97)
Wilson (0.49, 0.94) (0.40, 0.89) (0.49, 0.94) (0.49, 0.94) (0.49, 0.94) (0.49, 0.94)
The breakpoints were taken from www.eucast.org/clinical_breakpoints/ and then converted to µM. ∗Breakpoint of colistin was used. Tetracycline, kanamycin, and
erythromycin are not used in the clinic against P. aeruginosa and therefore exhibit no breakpoint. MIC values defined binary variables denoted as sensitive (below or equal
breakpoint) and resistant (above breakpoint) for the statistical analysis. SE: standard error, CI: confidence interval.
resistance compared to wt of differs significantly from 0.1 [all the
95% confidence intervals (CIs) are well above 0.1] even after a
conservative Bonferroni correction for multiple testing.
A set of short peptides between 9 and 13 amino acids in length
were selected from published and ongoing unpublished work
(Hilpert et al., 2005, 2006; Cherkasov et al., 2009; Mikut et al.,
2016); LL37 was used as a comparison peptide. LL37 is a long
(37mer) and helical peptide. The peptides are classified into four
peptide classes: class A: Bac2A variants, class B: LL37, class C:
RW-rich peptides, and class D: indolicidin variants. The MIC
values of the peptides against the wild-type P. aeruginosa strain as
well as three selected MDR variants of PA910, PA919, and PA253
were determined (Table 2). The majority of MIC values were
equal or similar (plus/minus factor of two) between the wild-
type and the MDR strains, with the highest change observed for
indolicidin with an eightfold decrease in activity. The MIC values
defined four classes according to their activity, where class 1 is the
most active with MIC values of 1–2 µM, class 2 includes peptides
with MIC values between 4 and 8 µM, class 3 includes peptides
with MIC values between 16 and 32 µM, and the least active class
includes peptides with MIC values larger than 32 µM. Statistical
analysis suggested that peptide classes C and D are associated
with stronger activity compared to class A (see Table 3). In
addition, comparisons between strains showed p-values less than
0.001 only between wt PA01 and PA910.
Strain PA 910, which is only sensitive to polymyxin B and
amikacin, was selected to perform a synergy study combining
31 AMPs with 12 antibiotics and one lipopeptide (polymyxin B)
resulting in 403 unique combinations (see Table 4).
The synergistic effects of combining short AMPs and
conventional antibiotics resulted in a complex pattern. There
were peptides that show no synergistic effect, while others showed
a variety, similar to the tested antibiotics (see Figures 1A,B).
For further statistical analysis, FIC values were transposed into
two classes, class 0 with FIC values larger than 0.5 and class 1 FIC
values equal or less than 0.5. P-values for the null hypothesis that
FIC values are similar were calculated comparing the antibiotics
and between peptide classes (see Table 5).
Selected peptide–antibiotic combinations were tested three
times to confirm first findings (see Table 6).
To test whether the observed synergy was dependent on the
selected strain or not, two additional MDR PA isolates (PA253
and PA919) were used to determine the FICs of the selected
peptides applied with polymyxin B (see Table 7).
DISCUSSION
Pseudomonas aeruginosa is ranked among the top five organisms
causing bloodstream, urinary tract, pulmonary, surgical site,
and soft tissue infections in patients in intensive care units
(Veesenmeyer et al., 2009). The bacterium is widely distributed in
the environment, as it can utilize a wide range of materials for its
nutrients, while only requiring a limited amount of nutrients to
survive (Abdelraouf et al., 2011). The current treatment regimen
for MDR cases is limited to the last resort antibiotic Colistin
(Hachem et al., 2007; Sabuda et al., 2008). Alarmingly, however,
P. aeruginosa resistance to colistin has been reported (Goli et al.,
2016). The situation is becoming increasingly disconcerting, and
the WHO has declared it a “critical priority pathogen,” on which
research and development of novel antibiotics should be focused
(Tacconelli et al., 2018).
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TABLE 2 | MIC values in µM of short AMPs (9-13mer) measured in triplicate (n = 3) against several isolates of MDR P. aeruginosa.
Name Amino acid sequence Class MIC against MDR isolates of PA/µM
PA01 wt PA910 PA919 PA253
Bac2a1 RLARIVVIRVAR-CONH2 A 16 (3) 32 (3) 16 (3) 32 (3)
G22 RGARIVVIRVAR-CONH2 A 32 (3) 32 (3) 16 (3) 32 (3)
R22 RRARIVVIRVAR-CONH2 A 32 (3) 32 (3) 16 (3) 32 (3)
W32 RLWRIVVIRVAR-CONH2 A 16 (3) 32 (3) 32 (3) 32 (3)
R32 RLRRIVVIRVAR-CONH2 A 16 (3) 32 (3) 16 (3) 16 (3)
W102 RLARIVVIRWAR-CONH2 A 16 (3) 16 (3) 16 (3) 16 (3)
R112 RLARIVVIRVRR-CONH2 A 16 (3) 64 (4) 32 (3) 64 (4)
Sub 32 RRWRIVVIRVRR-CONH2 A 8 (2) 16 (3) 16 (3) 8 (2)
Sub 7 RLWRIVVIRVKR-CONH2 A 16 (3) 32 (3) 32 (3) 16 (3)
Bac0343 VRLRIRVAVIRA-CONH2 A 32 (3) 64 (4) 32 (3) 64 (4)
W33 VRWRIRVAVIRA-CONH2 A 8 (2) 16 (3) 8 (2) 16 (3)
LL37 ## B 16 (3) 64 (4) 16 (3) 64 (4)
HHC-534 FRRWWKWFK-CONH2 C 8 (2) 32 (3) 16 (3) 8 (2)
LOP15 RWWRKIWKW-CONH2 C 2 (1) 8 (2) 2–4 (2) 8 (2)
LOP25 RRWWRWVVW-CONH2 C 4 (2) 8 (2) 2 (1) 8 (2)
LOP35 KRRWRIWLV-CONH2 C 4 (2) 8 (2) 4 (2) 4–8 (2)
LOP45 RRWRVIVKW-CONH2 C 4 (2) 4 (2) 4 (2) 8 (2)
LOP55 WKWLKKWIK-CONH2 C 4 (2) 8 (2) 8 (2) 8 (2)
Indolic.6 ILPWKWPWWPWRR-CONH2 D 8 (2) 32 (3) 32 (3) 64–128 (4)
Indopt 1 FIKWKKRWWKKRT-CONH2 D 4 (2) 8 (2) 32 (3) 16 (3)
Indopt 2 FIKWRFRRWKKRT-CONH2 D 4 (2) 8 (2) 32 (3) 16 (3)
Indopt 3 FIKWRSRWWKKRT-CONH2 D 4 (2) 8 (2) 32 (3) 16 (3)
Indopt 4 FIKWRFRRWKKRK-CONH2 D 4 (2) 4–8 (2) 16–32 (3) 8 (2)
Indopt 5 FIKWKFRPWKKRT-CONH2 D 4 (2) 8 (2) 16–32 (3) 16 (3)
Indopt 6 FIKRKSRWWKWRT-CONH2 D 4 (2) 8 (2) 32 (3) 8–16 (3)
Indopt 7 ILKWKRKWWKWFR-CONH2 D 2 (1) 4 (2) 32 (3) 8 (2)
Indopt 8 ILKWKKGWWKWFR-CONH2 D 4 (2) 4 (2) 16 (3) 8 (2)
Indopt 9 ILKWKRKWWKWRR-CONH2 D 1 (1) 2 (1) 16 (3) 4 (2)
Indopt 10 ILKWKIFKWKWFR-CONH2 D 2 (1) 4 (2) 32 (3) 8–16 (3)
Indopt 11 ILKWKTKWWKWFR-CONH2 D 2 (1) 4 (2) 16 (3) 4 (2)
Indopt 12 ILKWKMFKWKWFR-CONH2 D 2 (1) 4 (2) 16 (3) 16 (3)
MIC values of all Indopt variants were measured in 1/8 MHb, while all other were measured in full MHb. A 37mer human AMP was included as comparison (LL37). ##The
sequence of the peptide LL-37: LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES-COOH2. 1(Wu and Hancock, 1999a), 2(Hilpert et al., 2005), 3(Hilpert et al., 2006),
4(Cherkasov et al., 2009), 5(Mikut et al., 2016), 6(Selsted et al., 1992). The MIC values were compiled into four classes according to their activity, where class 1 is the most
active with MIC values of 1–2 µM, class 2 includes peptides with MIC values between 4 and 8 µM, class 3 includes peptides with MIC values between 16 and 32 µM,
and the least active class includes peptides with MIC values larger than 32 µM. The class values are shown in parentheses after the MIC values, e.g., 32(3) means MIC
value 32 µM belongs to class 3.
We confirmed the previously described multidrug resistance
of P. aeruginosa strains which were isolated in clinical
and municipal waste water (see Table 1; Schwartz et al.,
2006). Statistical tests showed very low p-values demonstrating
statistically significant differences between the susceptible wt
PA01 strain and the MDR strains. It has been reported that
AMPs show synergy with conventional antibiotics both in
planktonic and biofilm growth (Giacometti et al., 2000; Jorge
et al., 2017). Here we studied whether a set of short AMPs
which we developed in previous projects can synergize with
antibiotics in order to revive them. We also included polymyxin
B, since treatment failures with monotherapy of polymyxins
are reportedly increasing, making it an urgent candidate for
use with synergistic agents. Clinical trials investigating colistin
alone versus colistin in combination with meropenem are
currently underway (ClinicalTrials.gov IDs NCT01732250 and
NCT01597973) (Lenhard et al., 2016).
Bactenecin (RLCRIVVIRVCR-CONH2) is a cyclic
dodecapeptide found in bovine neutrophils. It is stored in
granules reaching concentrations of about 12 mg/ml and
is produced as a 155-mer precursor polypeptide (Romeo
et al., 1988; Storici et al., 1992). The peptide belongs to the
cathelicidine family. Using NMR spectroscopy, an antiparallel
β-sheet structure stabilized by a single disulfide bond was
detected (Raj et al., 2000). Synthetically produced bactenecin
demonstrated modest antibacterial activities against Gram-
negative and Gram-positive pathogens (Romeo et al., 1988;
Gallis et al., 1989; Wu and Hancock, 1999b). Linear variants
were produced, for example, Bac2A (RLARIVVIRVAR-CONH2)
which showed similar antibacterial activity and an improved
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TABLE 3 | Statistical analysis of activity classes based on MIC values given in
Table 2.
Outcome level/Class Class A Class C Class D Total
1 (Strong) 0 2 6 8
2 (Good) 4 20 24 48
3 (Medium) 36 2 21 59
4 (Weak) 4 0 1 5
Total 44 24 52 120
Comparison: classes Odds ratio P-value 95%CI—L 95%CI—H
C vs. A 47.56225 <0.001 13.22247 171.0852
D vs. A 15.43157 <0.001 5.267699 45.20632
C vs. D 3.08214 0.027 1.134687 8.371993
Comparison: strains PA01wt PA910 PA919 PA253
PA01wt p < 0.001 p = 0.308 p = 0.013
PA910 p = 0.721 p = 0.001
PA919 p = 0.119
PA253
toxicological profile (Wu and Hancock, 1999a). The cyclic
peptide bactenecin showed weak activity against artificial
membranes, and the cytoplasmatic membrane of Escherichia
coli was also only mildly disrupted at MIC concentrations
(Wu et al., 1999). In the case of Burkholderia pseudomallei,
bactenecin showed a strong binding with LPS, weak outer
membrane permeabilization, and medium activity monitoring
inner membrane disruption (Madhongsa et al., 2013). In the
case of tested linear variants, they caused a faster and almost
100% depolarization in E. coli, showing a distinctive different
pattern. In the case of Staphylococcus aureus, similar results
were obtained for linear bactenecin variants (Wu et al., 1999;
Hilpert et al., 2006). Linear bactenecin variants showed a random
structure in water, but a β-structure in contact with liposomes
(Hilpert et al., 2006). A complete substitution analysis of the
linear peptide Bac2A was performed using spot synthesis and a
luminescent variant of P. aeruginosa (Hilpert et al., 2005, 2007;
Hilpert and Hancock, 2007). This information led to various
variants that differ only slightly in sequence but strongly in
activity. In addition, scrambled variants were created and one of
them further investigated by substation analysis (Hilpert et al.,
2006). Bac2A and other variants were also shown to interact with
ATP and can inhibit luciferase, DnaK, and DNA polymerase
(Hilpert et al., 2010). The precise mechanism via which
bactenecin, Bac2A, and other linear variants kill the bacteria
is still unresolved but data indicate multiple mechanisms. The
peptide Bac2A showed synergistic interactions with five different
antibiotics, PMB, KAN, ERY, TET, and CIP. The exchange of
a single amino acid on position 2 or 3 (G2, R2, and W3) leads
to additional synergy with IMI. The single amino substitution
R2 and W10 lead to a strong additional synergistic effect with
MER. In contrast, the single amino acid substitution R11 reduced
the synergistic interaction to only one antibiotic, KAN. The
antibiotics CEF, PIP, TOB, and AMI did not exhibit any synergy
with this class of peptides.
The 9mer peptides HHC-53 and LOP1-5 are in silico predicted
peptides using different software (Cherkasov et al., 2009; Mikut
et al., 2016). The specific peptide HHC-53 was shown to be
effective in an invasive S. aureus mouse model. The mode of
action is unknown. Three of these 9mer peptides do not show any
synergy with the tested antibiotics. The peptide LOP3 exhibits the
most synergistic interaction in this class, which includes PMB,
MER, GEN, and ERY.
The 13mer peptide indolicidin (ILPWKWPWWPWRR-
CONH2) is, like bactenecin, a bovine peptide and also belongs to
the cathelicidin family. It is present in the cytoplasmic granules
of neutrophils (Selsted et al., 1992). The NMR structure reveals
that indolicidin forms an extended boat-like structure (Rozek
et al., 2000). The peptide is modestly active against various
Gram-positive and Gram-negative bacteria, but exhibits high
hemolytic activity and cytotoxicity (Selsted et al., 1992; Ahmad
et al., 1995). In Gram-negative bacteria, indolicidin interacts
with surface-exposed lipopolysaccharides (LPS), resulting in a
self-promoted uptake across the outer membrane, followed by
channel formation in the cytoplasmic membrane, leading to cell
death (Falla et al., 1996). Indolicidin has rather weak membrane
permeabilization characteristics (Wu et al., 1999). Similarly to
Bac2A, indolicidin seems to have multiple modes of action; it
interacts with ATP and can inhibit ATP dependent enzymes,
inhibits DNA/RNA synthesis, and inhibits protein synthesis
(Subbalakshmi and Sitaram, 1998; Hilpert et al., 2010). In this
study, optimized indolicidin variants are used in addition to
indolicidin itself. Variants Indopt1-6 show a similar pattern
compared to indolicidin itself. Indopt 2 and 3 also show synergy
with MER; Indopt 4 shows additional synergy to KAN and CIP.
Indopt 5 shows only two synergistic interactions, again showing
that small changes in the sequence can have a strong effect on the
synergy. Indopt 7-12 show only very few synergistic interactions.
The FICs between combinations of antibiotics and peptides
show several synergistic effects if antibiotics are used in tandem
with short AMPs. In general, the beta-lactams and beta-lactam-
like antibiotics show the lowest amount of synergy, along with
ciprofloxacin, a gyrase inhibitor, which also showed a rather
low amount of synergy. Cefepime and piperacillin showed
no detectable synergy at all. However, antibiotics acting on
the ribosome show a higher amount of synergy, with the
highest proportion of synergy observed in the use of polymyxin
B, which acts on the cell wall and cell membrane. The
majority of the results were confirmed by three independent
measurements of the selected combinations. Some combinations,
however, showed larger FIC values than determined in the
first screen, thus proving the importance of verifying FIC data
(Hsieh et al., 1993).
Polymyxin B binds to the lipid A portion of the LPS, to
replace cationic ions such as Ca2+ and Mg2+ from the LPS layer
(Morrison and Jacobs, 1976). This process destabilizes the LPS
layer, leading to permeability changes and consequently to a “self-
promoted uptake” (Hancock, 1997; Hermsen et al., 2003). This
process destabilizes the membrane and allows molecules to pass
through the membrane in both directions. It has been shown
that polymyxin B synergizes with antibiotics (Elemam et al., 2010;
Zusman et al., 2013; Abdul Rahim et al., 2015) as well with AMPs
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TABLE 4 | Fractional inhibitory concentrations (FICs) of short AMPs, 9-13mers, and different antibiotics were determined against an MDR isolate of P. aeruginosa
(PA 910).
Antibiotic
PMB CEF MER IMI PIP CET KAN TOB GEN AMI ERY TET CIP
MIC against PA910 in µM
0.13 128 >128 >128 64-128 64 128-256 32 128 2-4 128 64 64
Peptide Sequence MIC
against
PA910 in
µM
FIC values of combinations of peptides and short AMPs on PA910
Bac2a1 RLARIVVIRVAR-CONH2 32 0.38 2 2 0.63 1 0.75 0.38 1 0.75 1 0.5 0.5 0.5
G22 RGARIVVIRVAR-CONH2 32 0.38 2 0.51 0.5 0.56 0.63 0.56 0.53 0.75 1 0.38 0.63 0.5
R22 RRARIVVIRVAR-CONH2 32 2 2 0.26 0.5 0.56 0.51 0.38 2 0.75 1 0.27 0.38 0.63
W32 RLWRIVVIRVAR-CONH2 32 2 2 0.56 0.5 0.63 0.63 0.5 2 0.56 0.51 0.5 0.38 0.63
R32 RLRRIVVIRVAR-CONH2 32 0.63 0.63 0.51 0.75 0.56 1 0.56 0.63 0.5 2 0.5 0.5 0.75
Sub 32 RRWRIVVIRVRR-CONH2 16 0.56 0.56 2 0.63 1 0.75 1 2 n.d. 0.75 0.75 0.5 0.5
R112 RLARIVVIRVRR-CONH2 64 0.63 2 0.51 0.63 1 1 0.5 2 n.d. 2 0.53 0.53 0.53
Sub 7 RLWRIVVIRVKR-CONH2 32 1 0.56 0.51 2 0.53 0.56 0.63 2 n.d. 0.53 0.5 0.5 0.75
W102 RLARIVVIRWAR-CONH2 16 2 2 0.26 0.75 0.75 0.38 0.63 0.51 n.d. 0.75 0.5 0.29 0.56
S-W33 VRWRIRVAVIRA-CONH2 16 0.5 1 0.75 0.51 0.56 0.75 0.56 2 0.63 0.63 0.51 0.25 0.63
Bac0343 VRLRIRVAVIRA-CONH2 64 0.5 0.53 0.75 0.75 1 0.5 0.75 2 0.63 0.51 0.63 0.75 0.5
HHC-534 FRRWWKWFK-CONH2 32 0.56 2 0.53 1 0.63 1 0.5 0.5 0.63 0.53 0.75 0.63 1
LOP15 RWWRKIWKW-CONH2 8 0.75 2 1 1 0.63 0.51 0.75 2 0.75 0.51 0.53 0.63 0.75
LOP25 RRWWRWVVW-CONH2 8 0.56 2 1 0.75 0.63 2 0.56 2 2 2 0.75 0.75 0.63
LOP35 KRRWRIWLV-CONH2 8 0.38 0.53 0.5 0.75 0.56 0.75 1 0.63 0.5 0.75 0.5 1 0.63
LOP45 RRWRVIVKW-CONH2 4 1 2 0.63 2 2 2 0.75 0.75 1 1 0.5 0.56 0.75
LOP55 WKWLKKWIK-CONH2 8 0.38 0.56 0.5 0.51 0.51 0.5 2 2 0.63 1 0.75 0.63 1
Indolic.6 ILPWKWPWWPWRR-CONH2 32 0.5 2 0.63 0.63 0.56 0.51 0.75 0.5 0.5 0.5 0.63 0.5 1
Indopt 1 FIKWKKRWWKKRT-CONH2 8 0.25 0.56 0.75 0.63 0.63 1 0.63 0.38 0.25 0.38 0.75 0.56 1
Indopt 2 FIKWRFRRWKKRT-CONH2 8 0.25 0.56 0.5 0.63 0.56 1 0.75 0.25 0.25 0.31 0.75 0.5 0.75
Indopt 3 FIKWRSRWWKKRT-CONH2 8 0.38 0.56 0.38 0.63 0.63 1 0.75 0.38 0.25 0.31 0.53 1 0.75
Indopt 4 FIKWRFRRWKKRK-CONH2 4–8 0.25 2 0.63 0.75 0.53 1 0.5 0.25 0.38 0.31 0.53 0.5 0.5
Indopt 5 FIKWKFRPWKKRT-CONH2 8 0.38 2 0.75 1 0.75 2 0.75 0.56 0.38 0.63 0.53 0.75 1
Indopt 6 FIKRKSRWWKWRT-CONH2 8 0.38 0.63 0.75 0.75 0.75 2 0.5 0.38 0.25 0.38 1 0.5 0.75
Indopt 7 ILKWKRKWWKWFR-CONH2 4 0.38 0.53 0.53 2 2 1 2 0.38 0.75 0.5 0.5 0.75 0.75
Indopt 8 ILKWKKGWWKWFR-CONH2 4 0.38 2 0.63 0.75 0.56 0.75 1 0.5 0.75 0.63 0.5 0.56 0.75
Indopt 9 ILKWKRKWWKWRR-CONH2 2 0.75 2 0.63 2 0.75 2 0.75 0.63 0.63 0.5 0.75 0.75 0.75
Indopt 10 ILKWKIFKWKWFR-CONH2 4 0.75 2 0.5 0.63 1 0.56 2 0.75 0.63 0.75 0.38 1 1
Indopt 11 ILKWKTKWWKWFR-CONH2 4 0.5 2 1 0.75 0.53 1 0.56 0.75 0.75 0.75 0.56 0.63 1
Indopt 12 ILKWKMFKWKWFR-CONH2 4 0.75 2 1 1 0.51 1 1 0.75 0.75 0.63 0.5 2 1
LL37 ## 64 0.63 2 0.51 1 2 0.75 1 2 2 2 0.51 0.5 0.51
All FICs were determined once (n = 1) using MHb, for the Indopt versions, 1/8 MHb was used. FIC values equal to or less than 0.5 are considered as synergistic interaction
and highlighted in white on a black background. FIC values equal to or less than 0.6 (a 20% error margin) are considered as potentially synergistic and are labeled in
gray. PMB was used for the lipopeptide Polymyxin B, which acts on the cell wall and membrane, and is color coded in orange. Piperacillin (PIP) belongs to the class
ureidopenicillin, ceftazidime (CET) third-generation cephalosporin, cefepime (CEF) fourth-generation cephalosporin, and meropenem (MER) and imipenem (IMI) are part
of the carbapenem subgroup. They all act on the cell wall, especially cell wall synthesis, color coded in green. Tetracycline (TET), erythromycin (ERY), kanamycin (KAN),
tobramycin (TOB), amikacin (AMI), and gentamycin (GEN) all act at different sites of the bacterial ribosomes, color coded in light blue. Ciprofloxacin (CIP) is a gyrase
inhibitor and acts on the DNA replication system, color coded in gray. ##The sequence of the peptide LL-37: LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES-COOH2,
n.d. stands for not determined in this test. 1(Wu and Hancock, 1999a), 2(Hilpert et al., 2005), 3(Hilpert et al., 2006), 4(Cherkasov et al., 2009), 5(Mikut et al., 2016),
6(Selsted et al., 1992).
(Giacometti et al., 2000; van der Linden et al., 2009; Draper
et al., 2013). The majority of short cationic peptides used in
these studies also showed synergistic interaction with polymyxin
B (Table 4). This synergy was verified for two additional strains
(Table 5). Small changes in the sequence of Bac2A lead to a loss
in synergy, which is especially pronounced when a tryptophan
residue is introduced, for example, W3, Sub3, W10, and S-W3.
The data suggest that an additional tryptophan residue might
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FIGURE 1 | The maximum number of possible interactions was set to 100% and the percentage of synergistic interaction was calculated for (A) conventional
antibiotics and (B) short antimicrobial peptides. For color codes and abbreviations, see Table 4.
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TABLE 5 | Top section: p-values for the null hypothesis that FIC values of all combinations are similar. ∗For PIP and CEF, binomial tests were carried for the null hypothesis that the proportion equals 1/30 = 0.0333.
Bottom section: p-value calculated for three different peptide classes. The total sum of counts for synergy are given for each class with regard to each antibiotic.
Anti-biotics PMB CEF MER IMI PIP CET KAN TOB GEN AMI ERY TET CIP
PMB <0.000001 0.999 0.586 0.999 0.675 0.017 0.087 0.039 0.269 0.999 0.336
CEF∗ 0.000047 0.07714 0.625867 0.07714 0.000047 <0.000001 <0.000001 0.000005 <0.000001 <0.000001 0.002921
MER 0.999 0.128 0.999 0.999 0.628 0.999 0.666 0.999 0.304
IMI 0.999 0.128 0.534 0.529 0.545 0.07 0.548 0.433
PIP* 0.07714 0.000047 <0.000001 <0.000001 0.000005 <0.000001 <0.000001 0.002921
CET 0.999 0.534 0.529 0.545 0.999 0.999 0.433
KAN 0.64 0.999 0.999 0.999 0.084 0.565
TOB 0.028 <0.001 0.229 0.999 0.999
GEN 0.008 0.217 0.194 0.999
AMI 0.092 0.678 0.999
ERY 0.711 0.999
TET 0.364
CIP
Peptide Class PMB CEF MER IMI PIP CET KAN TOB GEN AMI ERY TET CIP
A 4 0 2 3 0 2 4 0 1 0 7 8 4
C 2 0 2 0 0 1 1 1 1 0 2 0 0
D 10 0 3 0 0 0 2 8 7 8 4 4 1
p-Values 0.09 NA 0.861 0.086 NA 0.286 0.534 0.002 0.17 <0.001 0.25 0.01 0.175
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TABLE 6 | Mean values (at least three measurements, n = 3) and standard deviations (values in brackets), of fractional inhibitory concentrations (FICs) of selected short AMPs, 9-13mers, and different antibiotics were
determined against an MDR isolate of P. aeruginosa (PA 910).
Peptide Antibiotic
PMB CEF MER IMI PIP CET KAN TOB GEN AMI ERY TET CIP
Bac2a1 0.47 (0.09) 0.63 (0.17) 0.69 (0.21) 0.44 (0.08) 1.08 (0.61)
G22 0.45 (0.16) 1.00 (0.70) 0.63 (0.25) 0.53 (0.01) 0.59 (0.11)
R22 1.09 (0.79) 1.00 (0.70) 0.63 (0.17) 0.42 (0.10) 0.38 (0.10)
W32 1.17 (0.72) n.d. 0.67 (0.11) 0.67 (0.11) 0.38 (0.25)
R32 0.46 (0.14) n.d. 0.67 (0.11) 1.04 (0.64) 0.46 (0.05)
Sub 32 0.50 (0.00) n.d.
R112 0.42 (0.14) 0.75 (0.17) 0.43 (0.12)
Sub 7 0.67 (0.31) n.d. 0.46 (0.06)
W102 n.d. n.d. n.d. 0.60 (0.27)
S-W33 0.81 (0.59) 0.46 (0.11) 0.34 (0.06)
Bac0343 0.43 (0.12) 0.59 (0.11) 0.58 (0.11) 0.50 (0.00) 0.50 (0.17) 0.75 (0.17)
HHC-534 0.46 (0.10) 0.60 (0.10) 0.54 (0.06) 0.52 (0.10)
LOP15 0.55 (0.18) 0.55 (0.19)
LOP25 0.60 (0.13)
LOP35 0.40 (0.04) 0.75 (0.17) 0.50 (0.00) 0.44 (0.08) 0.71 (0.19)
LOP45 n.d.
LOP55 0.38 (0.00) 0.54 (0.06) n.d. 0.50 (0.17) 0.50 (0.10)
Indolic.6 n.d. 0.71 (0.21) n.d. n.d. n.d.
Indopt 1 0.35 (0.10) 0.59 (0.14) 0.59 (0.29) 0.38 (0.00) 0.21 (0.03) 0.38 (0.00) 0.48 (0.18)
Indopt 2 0.38 (0.08) 0.54 (0.06) 0.29 (0.03) 0.19 (0.04) 0.32 (0.04) 0.75 (0.17)
Indopt 3 0.33 (0.06) 0.38 (0.00) 0.33 (0.06) 0.23 (0.10) 0.37 (0.08) 0.47 (0.06)
Indopt 4 0.29 (0.06) 0.50 (0.09) 0.60 (0.10) 0.27 (0.07) 0.23 (0.03) 0.31 (0.04) 0.59 (0.10) 0.63 (0.25)
Indopt 5 0.33 (0.06) 0.47 (0.19) 0.52 (0.03) 0.35 (0.03) 0.55 (0.05)
Indopt 6 0.38 (0.00) 0.52 (0.15) 0.55 (0.06) 0.38 (0.08) 0.27 (0.07) 0.38 (0.00) 0.50 (0.00)
Indopt 7 0.38 (0.00 0.67 (0.22) 0.55 (0.05) 0.50 (0.00)
Indopt 8 0.29 (0.06) 0.54 (0.06) 0.58 (0.11) 0.45 (0.07)
Indopt 9 0.54 (0.14) 0.46 (0.14) 0.51 (0.01)
Indopt 10 0.46 (0.19) 0.52 (0.03) 0.63 (0.17) 0.38 (0.00)
Indopt 11 0.46 (0.06) 0.52 (0.15)
Indopt 12 0.48 (0.18) 0.59 (0.06)
LL37 n.d.
FICs were determined in MHb, for the Indopt versions, where 1/8 MHb was used. FIC values equal to or less than 0.5 are considered as synergistic interaction and highlighted in white on a black background. FIC values
equal to or less than 0.6 (a 20% error margin) are considered as potentially synergistic and are labeled in gray. See Table 3 for color codes and abbreviations. All peptides that showed FIC values equal to or less than
0.5 in the first experiment (see Table 3) which were not included in this confirmation study are labeled with n.d.
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TABLE 7 | FIC values of selected peptides for three different MDR P. aeruginosa
strains against polymyxin B.
Name Sequence MDR-PA910 MDR-PA253 MDR-PA919
Indopt 4 FIKWRFRRWKKRK-CONH2 0.29 0.29 0.38
Indopt 8 ILKWKKGWWKWFR-CONH2 0.29 0.31 0.38
Indopt 3 FIKWRSRWWKKRT-CONH2 0.33 0.19 0.38
Indopt 5 FIKWKFRPWKKRT-CONH2 0.33 0.13 0.38
Indopt 1 FIKWKKRWWKKRT-CONH2 0.35 0.38 0.38
Indopt 2 FIKWRFRRWKKRT-CONH2 0.38 0.31 0.38
Indopt 6 FIKRKSRWWKWRT-CONH2 0.38 0.26 0.38
Indopt 7 ILKWKRKWWKWFR-CONH2 0.38 0.52 0.29
LOP5 WKWLKKWIK-CONH2 0.38 0.25 0.38
LOP3 KRRWRIWLV-CONH2 0.40 0.31 0.56
R11 RLARIVVIRVRR-CONH2 0.42 0.56 0.56
Bac034 VRLRIRVAVIRA-CONH2 0.43 0.38 0.38
HHC53 FRRWWKWFK-CONH2 0.46 0.63 0.50
Indopt 10 ILKWKIFKWKWFR-CONH2 0.46 0.50 0.38
Indopt 11 ILKWKTKWWKWFR-CONH2 0.46 0.50 0.29
R3 RLRRIVVIRVAR-CONH2 0.46 0.50 0.63
Indopt 12 ILKWKMFKWKWFR-CONH2 0.48 0.50 0.27
Indopt 9 ILKWKRKWWKWRR-CONH2 0.54 0.63 0.50
Sub7 RLWRIVVIRVKR-CONH2 0.67 0.50 0.50
Values from MDR-PA910 are mean values from at least three different
measurements; values from MDR-PA253 and MDR-PA919 are measured once.
The table is sorted according to the values from MDR-PA910, from low to high.
anchor the peptide more in the membrane and consequently does
not support synergy with polymyxin B.
Cefepime is a fourth-generation cephalosporin antibiotic that
has an extended spectrum of activity against Gram-positive and
Gram-negative bacteria and is more stable compared to third-
generation agents (Wynd and Paladino, 1996). Cephalosporins
are bactericidal that disrupts the synthesis of the peptidoglycan
layer of the bacterial cell walls by blocking transpeptidases
known as penicillin-binding proteins (PBPs) (Klein and Cunha,
1995). There was no synergistic effect observed, indicating
that the peptides did not improved access to target sites or
that they interfered with the lactamases. Ceftazidime is a
third-generation cephalosporin antibiotic targeting PBPs.
Similar to cefepime, there were no synergistic combinations
determined with the exception of Bac034, W10, and LOP5.
Meropenem, a carbapenem-type beta-lactam antibiotic active
against Gram-positive and Gram-negative bacteria, blocks
PBPs and shows a bactericidal activity (Blumer, 1997). In
contrast to cefepime, a range of short AMPs showed synergistic
interaction. Imipenem on the other hand, another carbapenem-
type beta-lactam with the same mode of action, did show
three synergistic interactions; however, in the confirmation
experiment (Table 4), these were not verified (Park and Parker,
1986). We conclude that synergy is caused by a meropenem-
specific feature, for example, increasing the uptake rate for
this molecule. Piperacillin is a penicillin beta-lactam antibiotic
used clinically mainly for Gram-negative organisms and
demonstrates bactericidal activity as a result of the inhibition
of cell wall synthesis by binding to PBPs. Piperacillin is
stable against hydrolysis by a variety of beta-lactamases,
including penicillinases, cephalosporinases, and extended
spectrum beta-lactamases (Eliopoulos and Moellering, 1982). No
synergistic combinations were observed for piperacillin with the
short AMPs tested.
Kanamycin (kanamycin A) belongs to the aminoglycoside
class and is a natural compound found in Streptomyces
kanamyceticus (de Lima Procópio et al., 2012). Aminoglycosides
bind to the 30S subunit of the ribosome: most binding
occurs on the 16 srRNA of the bacteria leading to a
bactericidal action (Walter et al., 1999). It shows broad-
spectrum activity against Gram-negative bacteria and some
activity against Gram-positive. Of all the aminoglycosides,
kanamycin shows the least activity and the least confirmed
synergy. Tobramycin is produced in Streptomyces tenebrarius
and belongs to the class of aminoglycoside antibiotics. It binds
irreversibly to the 30S ribosomal subunit and shows a broad-
spectrum activity, especially effective against P. aeruginosa3.
Gentamicin is an aminoglycoside antibiotic that is produced
by Micromonospora purpurea and acts on the 30S subunit.
It is highly active against Gram-negative bacteria and shows
activity against some Gram-positive bacteria (Daniels et al.,
1975). Amikacin is a semi-synthetic antibiotic based on
kanamycin A, both members of the class aminoglycosides,
which binds to the 30S subunit and 16 srRNA. Amikacin
demonstrates a broad-spectrum activity toward Gram-negative
bacteria, including pseudomonades, and has some effects on
Gram-positive bacteria, including S. aureus (Ristuccia and
Cunha, 1985). Indolicidin and Indopt1, 2, 3, 4, and 6 show
strong synergistic interactions with tobramycin, gentamycin,
and amikacin. This observation is in accordance with research
published by Boehr et al. (2003), showing that indolicidin
and analogs (differ from the ones in this study) are able to
inhibit aminoglycoside phosphotransferase and aminoglycosides
acetyltransferase. Through the inhibition of these enzymes,
the most effective resistance mechanism in the bacteria can
be weakened and activity of the antibiotics gained (Boehr
et al., 2003). Based on these findings, a further optimization
of Indopt peptides could lead to the creation of more
potent aminoglycoside phosphotransferase and aminoglycosides
acetyltransferase inhibitors that can be used for a combination
therapy to overcome aminoglycosides resistance.
Erythromycin is a macrolide antibiotic produced by
Saccharopolyspora erythraea and reversibly binds to the
50S subunit of the bacterial ribosome4. It is active against
Gram-negative and Gram-positive bacteria. Tetracycline is
a naturally produced antibiotic by Streptomyces aureofaciens
and binds reversibly to the 30S subunit as well as to some
extent the 50S subunit, with potential influence over the
bacterial membrane5. Tetracycline belongs to the class of
tetracyclines and is a broad-spectrum antibiotic with activity
against Gram-positive and Gram-negative bacteria. The
synergy patterns for these two classes appear different from the
aminoglycosides. A broader range of peptides can synergize with
3https://www.drugbank.ca/drugs/DB00684
4https://www.drugbank.ca/drugs/DB00199
5https://www.drugbank.ca/drugs/DB00759
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these antibiotics, for example, Bac2A variants, 9mer variants, and
the indolicidin variants.
Ciprofloxacin is a synthetic antibiotic belonging to
the fluoroquinolones and is an inhibitor of the bacterial
topoisomerase II (DNA gyrase) and topoisomerase IV.
Ciprofloxacin is a broad-spectrum antibiotic with a wide range
of Gram-positive and Gram-negative bacteria6. Only a few
peptides, Bac2A, G2, Sub3, and Indopt4, show synergy, all at
0.5, and confirmation studies showed even higher values for the
selected combinations.
The perception of peptides as drugs is only slowly changing,
despite the fact that in various cases, their value has been
demonstrated. Over the last 30 years, more than 100 peptide-
based drugs have been released for clinical use against a variety
of pathologies including: diabetes, cancer, obesity, cardiovascular
disease, inflammation, and osteoporosis; generating a net revenue
of over US$40 billion annually (Mäde et al., 2014). Peptide-based
drugs have multiple advantages, such as ease of synthesis and
scalability as well as known degradation pathways leading to non-
toxic by-products. As a result, in the years from 2016 to 2024, the
growth in the development of peptide-based drugs is expected to
rise by 9.1% and exceed US$70 billion in revenue by the end of
2019 (Lee et al., 2019).
Delivery of peptides are usually by injection, intravenous
(IV), intramuscular (IM), by a catheter, by inhalation, or by
subdermal osmotic pumps. Oral bioavailability is usually rather
low. When further investigating AMPs for synergistic interaction
in mouse models, we believe that IV delivery or the usage of
an osmotic pump will be most relevant to draw conclusions
for application in humans. Peptides HHC-53 and HHC-10
(9mer peptide from same study) were used in an invasive
S. aureus mouse model and application of peptides was done
by intraperitoneal (IP) for both peptides and IV for HHC-
10. Recently, Knappe et al. (2019) have shown that the use
of an osmotic pump leads to stable plasma levels that in
consequence enhanced the survival rate compared to IV and IM
administration. In our opinion, further in vivo studies for synergy
should be performed when drug formulation and delivery is
optimized. The oral availability of most antibiotics described
here will ease the study of peptide–antibiotic synergy in vivo
since two different delivery modes can be applied, controlling the
required concentrations.
6 https://www.drugbank.ca/drugs/DB00199
CONCLUSION
In summary, our data show that small AMPs that can kill MDR
bacteria, in this case MDR P. aeruginosa, are able to synergize
with conventional antibiotics despite the fact that they are no
longer effective. We believe that this shows the potential to
develop these molecules not only as mono-therapeutic agents,
but also as part of a combination therapy with the conventional
antibiotics in order to reuse antibiotics via this synergistic
approach with AMPs. This may be an alternative method for
dealing with the resistance crisis. The data also show that small
changes in the sequence can have quite dramatic effects on
synergy, making it possible to optimize novel drugs toward
desired synergistic effects.
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